Secarna Pharmaceuticals has announced that the Inhaled Nanocarriers with Antisense Therapy for lung fibrosis (INAT) project has received a 3-year grant to fund from the ERA-Net Cofund EuroNanoMed3, part of the EC’s Horizon 2020 Framework Program for Research and Innovation. Secarna is part of a consortium for INAT that includes French, German, and Belgian universities and French nanotechnology company Divincell.
The INAT project is developing an aerosol therapy that will deliver a Secarna antisense oligonucleotide formulated with a Divincell nanocarrier to the lung, where it is meant to inhibit a gene associated with IPF. Another project funded by EuroNanoMed3, ARROW-NANO is developing lipid nanovectors for inhaled therapies meant to treat lung diseases such as bronchiolitis obliterans syndrome and systemic sclerosis associated interstitial lung disease.
Secarna Managing Director and Co-founder Jonas Renz commented, “We are proud to receive funding for INAT under Horizon 2020 to develop inhaled nanocarriers loaded with our antisense oligonucleotides as a novel nanomedicine for lung fibrosis, a chronic and incurable disease with an average survival time of only two to five years. This grant showcases the attractiveness of Secarna’s LNAplus platform and broad therapeutic applicability. Together with our partners we are looking forward to collaborating on this highly promising approach for IPF.”
Read the Secarna press release.
